Sarepta Therapeutics Quarterly Cash Flow Statement
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sarepta Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Sarepta Therapeutics generated $197.1 million of operating cash flow and spent $555,000 on capital expenditures. That left free cash flow of $196.5 million, a free-cash-flow margin of 49.0% of revenue. Free cash flow was down 14.4% from the prior year's $229.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Sarepta Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -4.89M | 330.96M | -282.85M | -179.95M | 196.89M | -447.51M | 159.05M | 33.61M | 6.46M | 36.12M | 45.66M | -40.94M |
| Net Income growth (YoY) | -102.48% | — | -277.84% | -635.38% | +2947.86% | -1338.98% | +248.37% | — | — | — | — | — |
| Depreciation & Amortization | 10.41M | 10.59M | 5.25M | 18.45M | 10.84M | 9.98M | 10.46M | 9.81M | 8.72M | 8.74M | 11.37M | 10.93M |
| Stock-Based Compensation | 24.47M | 29.40M | 30.02M | 14.93M | 37.02M | 41.43M | 49.68M | 43.45M | 50.48M | 40.69M | 45.83M | 48.06M |
| Change in Working Capital | 111.47M | -626.29M | 78.13M | 75.74M | 45.37M | -361.89M | -296.16M | -186.11M | -64.67M | -91.72M | -190.96M | -143.68M |
| Operating Cash Flow | 197.07M | -202.68M | 131.21M | -14.59M | 261.34M | -583.44M | 92.05M | -70.70M | 14.94M | -242.08M | -54.66M | -114.71M |
| Capital Expenditures | -555.00K | -2.08M | -3.59M | -22.93M | -31.80M | -43.65M | -38.08M | -37.26M | -29.17M | -32.44M | -19.04M | -29.67M |
| Investing Cash Flow | -93.37M | -134.39M | 96.21M | 232.40M | 32.21M | -291.18M | 764.12M | -128.82M | -98.53M | 218.80M | -64.36M | -210.57M |
| Share Repurchases | — | — | 0 | 0 | — | — | 0 | 0 | — | — | — | — |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Financing Cash Flow | 0 | 241.00K | -39.21M | -117.79M | -23.82M | 12.47M | 48.99M | 13.76M | 39.92M | 22.14M | 1.94M | 15.40M |
| Net Change in Cash | 103.70M | -336.83M | 188.21M | 100.03M | 269.73M | -862.14M | 905.15M | -185.77M | -43.67M | -1.14M | -117.07M | -309.87M |
| Free Cash Flow | 196.51M | -204.76M | 127.61M | -37.52M | 229.54M | -627.09M | 53.96M | -107.96M | -14.22M | -274.52M | -73.70M | -144.38M |
This table shows 12 quarterly periods of Sarepta Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SRPT's reporting calendar. What is a cash flow statement?